1. Scrip
  2. >>Business

In Seeking ‘Strategic Alternatives’ Avrobio Is Confronting Gene Therapy Reality

Acquisition Or Merger Are Hoped For Exits

 
• By Andrew McConaghie

Avrobio is facing up to the reality of investor skepticism about gene therapy platforms and business models – but can it find a buyer or merger partner to start again?

Avrobio

Avrobio has announced that it is to halt all drug development in its gene therapy pipeline, and begin a “comprehensive exploration of strategic alternatives” to maximize shareholder value.

The Cambridge, MA-based biotech said this could include an acquisition, merger, business combination, or other transaction – but warned investors that there was no guarantee any

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.